FDA approvals in 2023: biomarker-positive subsets, equipoise and verification of benefit

Nat Rev Clin Oncol. 2024 May;21(5):333-334. doi: 10.1038/s41571-024-00871-5.

Authors

Kelly J Norsworthy¹, Rosa J Lee-Alonzo², Richard Pazdur²

Affiliations

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. [email protected].
² Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.

PMID: 38383759
DOI: 10.1038/s41571-024-00871-5

No abstract available

MeSH terms

Biomarkers, Tumor* / genetics
Drug Approval*
Humans
Neoplasms / drug therapy
Neoplasms / genetics
Vereinigte Staaten
United States Food and Drug Administration*

Substances

Biomarkers, Tumor